Alcoholism-Associated Molecular Adaptations In Brain Neurocognitive Circuits

Main Category: Alcohol / Addiction / Illegal Drugs
Also Included In: Conferences;  Neurology / Neuroscience
Article Date: 09 Jul 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

After many years of heavy drinking, alcohol produces pathological alterations in the brain. In many alcoholics these changes culminate in massive social deterioration and disorders of memory and learning. Severe cognitive impairments occur in approximately 10% of heavy drinkers. Alcoholic dementia is the second leading course of adult dementia in the Western countries, accounting for 10% of the cases, and still represents an unresolved problem. So far no effective pharmacotherapy for memory problems in alcoholics is available.

Nowadays this problem can be approached by innovative research using molecular and epigenetic analyses, which yield new insight into brain pathophysiology. Molecular dysregulations in endogenous opioids - a neurotransmitter system in the brain that is central to reward function and pain control - are supposed to play a critical role in the development of alcoholism and associated cognitive impairment.

Professor Georgy Bakalkin, involved in a research team focusing on biochemical mechanisms underlying neuropsychiatric disorders, will highlight the latest findings on this clinical challenge and presents a novel mechanism and understanding of cognitive deficit in human alcoholics. Thereby an emerging concept that proposes a new target for pharmacotherapy will be discussed, which might lead to innovative therapeutic interventions to improve or prevent alcohol-induced cognitive impairment in patients with alcohol dependence, and may be generalized to other learning and memory disorders.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

SPEAKER: Professor Georgy Bakalkin, Division of Biological Research on Drug Dependence, Department of Pharmaceutical Biosciences, Uppsala University, Sweden. Press conference on 2 September 2008 in Barcelona, Spain.

Source: Sonja Mak
European College of Neuropsychopharmacology